Research output per year
Research output per year
Personal profile
Research interests
Optimal design of population PK/PD experiments
Sample size calculation for population PK/PD experiments
Modelling of population PK/PD experimental data
Computer aided clinical trial simulation
Physiologically-based pharmacokinetic modelling
Pharmacokinetics in special population (Children)
Qualifications
1998, BPharm (Obafemi Awolowo University, Ile-Ife, Nigeria)
2005, PhD (The University of Manchester, Manchester, UK)
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Kayode Ogungbenro is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Covariates in population pharmacokinetic studies of critically ill adults receiving β-lactam antimicrobials: a systematic review and narrative synthesis
Hansel, J., Mannan, F., Robey, R., Kumarendran, M., Bladon, S., Mathioudakis, A., Ogungbenro, K., Dark, P. & Felton, T., 26 Feb 2024, In: JAC-Antimicrobial Resistance. 6, 1, dlae030.Research output: Contribution to journal › Article › peer-review
Open Access -
Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis
Ling, S. F., Ogungbenro, K., Darwich, A. S., Ariff, A. B. M., Nair, N., Bluett, J., Morgan, A. W., Isaacs, J. D., Wilson, A. G., Hyrich, K. L., Barton, A. & Plant, D., 23 May 2024, In: Pharmaceutics. 16, 6, 702.Research output: Contribution to journal › Article › peer-review
Open Access -
A "middle-out approach" for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models
Yau, E., Gertz, M., Ogungbenro, K., Aarons, L. & Olivares-Morales, A., 1 Mar 2023, In: CPT: Pharmacometrics and Systems Pharmacology. 12, 3, p. 346-359 14 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Development of a sensitive biochemical assay for the detection of tofacitinib adherence
Church, S., Hyrich, K. L., Ogungbenro, K., Unwin, R. D., Barton, A. & Bluett, J., 6 Apr 2023, In: Analytical Methods. 15, 14, p. 1797-1801 5 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in Children
Cleary, Y., Kletzl, H., Grimsey, P., Heinig, K., Ogungbenro, K., Silber Baumann, H. E., Frey, N., Aarons, L., Galetin, A. & Gertz, M., 1 Jun 2023, In: Clinical Pharmacokinetics. 62, 6, p. 891-904 14 p.Research output: Contribution to journal › Article › peer-review
Open Access
Impacts
-
Modernising Drug Development Practices for Precision Dosing in Diverse Patient Populations
Rostami-Hochaghan, A. (Participant), Aarons, L. (Participant), Galetin, A. (Participant), Barber, J. (Participant), Ogungbenro, K. (Participant) & (Participant)
Impact: Technological impacts, Economic, Health and wellbeing, Policy